Antonella d'Arminio Monforte

List of Publications by Year
in descending order

360 papers	31,501 citations	8732 75 h-index	4628 170 g-index
368 all docs	368 docs citations	368 times ranked	24486 citing authors

#	Article	IF	Citations
1	Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 2020, 382, 2327-2336.	13.9	2,241
2	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	13.9	1,560
3	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	6.3	1,415
4	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	13.9	1,393
5	Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, The, 1998, 352, 1725-1730.	6.3	1,182
6	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, The, 2003, 362, 22-29.	6.3	1,157
7	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	4.3	1,004
8	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	6.3	809
9	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV,the, 2017, 4, e349-e356.	2.1	805
10	Cardiovascular disease risk factors in HIV patients â€“ association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-1193.	1.0	770
11	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, The, 2014, 384, 241-248.	6.3	767
12	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, The, 2009, 373, 1352-1363.	6.3	676
13	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Antiâ€HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2010, 201, 318-330.	1.9	575
14	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naÃ¯ve patients. Aids, 2000, 14, 499-507.	1.0	483
15	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. Diabetes Care, 2008, 31, 1224-1229.	4.3	448
16	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 445-449.	0.9	405
17	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S123-S127.	0.9	390
18	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Aids, 2010, 24, 1537-1548.	1.0	381

#	Article	IF	Citations
19	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-93.	1.0	335
20	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	3.1	309
21	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	6.3	303
22	Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, S3-S8.	0.9	274
23	Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of Neurology, 2004, 55, 320-328.	2.8	273
24	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, The, 2019, 393, 143-155.	6.3	265
25	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids, 2007, 21, 1185-1197.	1.0	264
26	Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. Aids, 2002, 16, 1663-1671.	1.0	259
27	Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. Aids, 2008, 22, 2035-2038.	1.0	256
28	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
29	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV,the, 2015, 2, e98-e106.	2.1	249
30	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. Psychosomatics, 2004, 45, 394-402.	2.5	231
31	Female gender is associated with long COVID syndrome: a prospective cohort study. Clinical Microbiology and Infection, 2022, 28, 611.e9-611.e16.	2.8	230
32	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationÂ. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
33	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet, The, 2006, 368, 451-458.	6.3	209
34	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Aids, 2008, 22, 2143-2153.	1.0	207
35	Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet, The, 1999, 353, 1293-1298.	6.3	206
36	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases, 2005, 41, 1772-1782.	2.9	197

#	Article	IF	Citations
37	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
38	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. European Journal of Preventive Cardiology, 2016, 23, 214-223.	0.8	180
39	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal of Epidemiology, 2009, 38, 1624-1633.	0.9	173
40	Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction. Journal of Infectious Diseases, 1992, 165, 720-723.	1.9	161
41	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). Journal of NeuroVirology, 2003, 9, 47-53.	1.0	157
42	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV,the, 2016, 3, e23-e32.	2.1	157
43	Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine, 2001, 344, 168-174.	13.9	155
44	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. Aids, 2011, 25, 1385-1394.	1.0	155
45	The Absence of CD4+T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. Clinical Infectious Diseases, 2009, 48, 328-337.	2.9	150
46	Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 951-959.	0.9	149
47	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Nonâ€“AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	1.9	146
48	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	11	145
49	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	0.9	142
50	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
51	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 2014, 59, 287-297.	2.9	136
52	Prevalence, Associated Factors, and Prognostic Determinants of AIDSâ€Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 39, 1681-1691.	2.9	131
53	The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523.	1.2	129
54	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. Aids, 2006, 20, 1727-1736.	1.0	127

#	Article	IF	Citations
55	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. Archives of Internal Medicine, 2005, 165, 416.	4.3	124
56	Relationship between current level of immunodeficiency and nonâ€acquired immunodeficiency syndromeâ€defining malignancies. Cancer, 2010, 116, 5306-5315.	2.0	120
57	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. Clinical Infectious Diseases, 2004, 38, 565-571.	2.9	118
58	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. Journal of Infectious Diseases, 2002, 185, 178-187.	1.9	116
59	Anxiety and depression symptoms after virological clearance of COVIDâ€19: A crossâ€sectional study in Milan, Italy. Journal of Medical Virology, 2021, 93, 1175-1179.	2.5	115
60	Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376.	4.6	109
61	Variable Impact on Mortality of AIDSâ€Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDSâ€Defining Conditions Are Created Equal. Clinical Infectious Diseases, 2009, 48, 1138-1151.	2.9	108
62	Long-Lasting Cognitive Abnormalities after COVID-19. Brain Sciences, 2021, 11, 235.	1.1	107
63	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	0.6	103
64	Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. Aids, 2004, 18, 227-235.	1.0	102
65	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European caseâ€“control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	1.3	102
66	Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy. PLoS ONE, 2011, 6, e18580.	1.1	97
67	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count â‰¥200 Cells/ÂµL in the Postâ€“Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
68	Potential predictive factors of osteoporosis in HIV-positive subjects. Bone, 2006, 38, 893-897.	1.4	90
69	Body Habitus Changes and Metabolic Alterations in Protease Inhibitorâ€“Naive HIV-1â€“Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 21-31.	0.9	89
70	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. Aids, 2013, 27, 407-415.	1.0	89
71	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. Circulation, 2009, 119, 805-811.	1.6	88
72	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88

#	Article	IF	Citations
73	When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. Aids, 2001, 15, 983-990.	1.0	87
74	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160460.	1.1	86
75	Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992.	1.0	79
76	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. Aids, 2010, 24, 427-435.	1.0	76
77	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virusâ€"Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases, 2017, 65, 959-966.	2.9	75
78	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. Aids, 2013, 27, 769-779.	1.0	70
79	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
80	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	1.3	68
81	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	5.8	67
82	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy, 2008, 13, 959-967.	0.6	65
83	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. Journal of NeuroVirology, 2001, 7, 364-368.	1.0	64
84	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 184-190.	0.9	64
85	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. Journal of Virology, 2006, 80, 7186-7198.	1.5	64
86	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal of Epidemiology, 2014, 43, 691-702.	0.9	64
87	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. Journal of Virology, 2007, 81, 11507-11519.	1.5	62
88	Medical and Societal Consequences of Late Presentation. Antiviral Therapy, 2010, 15, 9-15.	0.6	61
89	T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis. PLoS ONE, 2012, 7, e46073.	1.1	61
90	Patient-reported and physician-estimated adherence to HAART. Journal of General Internal Medicine, 2004, 19, 1104-1110.	1.3	60

#	Article	IF	Citations
91	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS ONE, 2017, 12, e0186638.	1.1	59
92	Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 2015-2025.	1.4	58
93	Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. Aids, 2003, 17, 1099-1102.	1.0	58
94	AIDS-defining diseases in 250 HIV-infected patients; a comparative study of clinical and autopsy diagnoses. Aids, 1992, 6, 1159-1164.	1.0	57
95	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. Journal of Antimicrobial Chemotherapy, 2010, 65, 2305-2318.	1.3	57
96	Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV,the, 2019, 6, e869-e877.	2.1	57
97	Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. Infection, 2009, 37, 445-449.	2.3	56
98	Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990â€“2014. Journal of Hepatology, 2017, 67, 255-262.	1.8	56
99	Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipidâ€Lowering Drugs in HIVâ€Infected Individuals and Impact on Myocardial Infarction. Clinical Infectious Diseases, 2008, 46, 1101-1110.	2.9	55
100	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. Aids, 2016, 30, 991-1003.	1.0	55
101	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Journal of the International AIDS Society, 2012, 15, 17426.	1.2	54
102	Oneâ€year cognitive followâ€up of COVIDâ€19 hospitalized patients. European Journal of Neurology, 2022, 29, 2006-2014.	1.7	54
103	Risk of Developing Specific AIDSâ€Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. Clinical Infectious Diseases, 2009, 49, 612-622.	2.9	53
104	Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. Aids, 2004, 18, 11-19.	1.0	52
105	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Aids, 2008, 22, 2461-2469.	1.0	51
106	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Journal of Antimicrobial Chemotherapy, 2010, 65, 548-555.	1.3	51
107	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested caseâ€control study. BMC Infectious Diseases, 2013, 13, 414.	1.3	51
108	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	1.0	51

#	Article	IF	Citations
109	High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. Journal of Virology, 2005, 79, 10718-10729.	1.5	50
110	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	1.0	50
111	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 2008, 13, 959-67.	0.6	50
112	Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. Aids, 2008, 22, 1769-1778.	1.0	48
113	Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. Journal of Translational Medicine, 2013, 11, 51.	1.8	48
114	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV,the, 2022, 9, e474-e485.	2.1	48
115	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 407-416.	0.9	46
116	Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals. Clinical Infectious Diseases, 2005, 40, e101-e109.	2.9	46
117	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	2.9	46
118	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
119	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. Frontiers in Immunology, 2020, 11, 580987.	2.2	46
120	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. Antiviral Therapy, 2011, 16, 1103-1112.	0.6	45
121	Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 23-30.	0.9	44
122	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	0.9	43
123	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. Journal of Hepatology, 2013, 59, 213-220.	1.8	41
124	Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 348-354.	0.9	41
125	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 229-237.	0.9	40
126	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Aids, 2009, 23, 2199-2208.	1.0	40

#	Article	IF	Citations
127	Discontinuation of Secondary Prophylaxis forPneumocystis cariniiPneumonia in Human Immunodeficiency Virusâ€"Infected Patients: A Randomized Trial by the CIOP Study Group. Clinical Infectious Diseases, 2003, 36, 645-651.	2.9	39
128	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. Aids, 2011, 25, 1497-1504.	1.0	39
129	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	1.0	39
130	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 263-271.	0.9	39
131	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. Antiviral Therapy, 2006, 11, 567-574.	0.6	38
132	Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients. AIDS Research and Human Retroviruses, 2006, 22, 386-392.	0.5	37
133	Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern. Infection, 2017, 45, 1-10.	2.3	36
134	Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. Aids, 1997, 11, 517-524.	1.0	35
135	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. Antiviral Therapy, 2010, 15, 1077-1086.	0.6	35
136	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323.	1.0	35
137	Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. Aids, 2001, 15, 1733-1736.	1.0	35
138	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	0.9	34
139	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. Journal of Infectious Diseases, 2016, 214, 1212-1220.	1.9	34
140	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. AIDS Patient Care and STDs, 2008, 22, 291-299.	1.1	33
141	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 2009, 32, 474-480.	4.3	33
142	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. Aids, 2010, 24, 1455-1460.	1.0	33
143	Hepatitis C seroconversions in <scp>HIV</scp> infection across Europe: which regions and patient groups are affected?. Liver International, 2015, 35, 2384-2391.	1.9	33
144	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. Antiviral Therapy, 2004, 9, 291-296.	0.6	32

#	Article	IF	Citations
145	Clinical diagnosis of mycobacterial diseases versus autopsy findings in 350 patients with AIDS. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 453-458.	1.3	31
146	Multiple viral infections. Journal of Hepatology, 2006, 44, S108-S113.	1.8	31
147	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study â€“ 2012 â€“ 2015. PLoS ONE, 2019, 14, e0220108.	1.1	31
148	Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551.	1.3	31
149	Behavioral Correlates of Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S145-S148.	0.9	30
150	Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. International Journal of Antimicrobial Agents, 2005, 26, 88-91.	1.1	30
151	Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy. Frontiers in Immunology, 2016, 7, 614.	2.2	30
152	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE, 2017, 12, e0186549.	1.1	29
153	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.4	28
154	Outcome of a Second-Line Protease Inhibitorâ€“Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 115-122.	0.9	27
155	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 2016, 22, 191-200.	2.8	27
156	HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious Diseases and Therapy, 2021, 10, 2051-2070.	1.8	26
157	Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals. Antiviral Therapy, 2005, 10, 109-117.	0.6	26
158	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. Clinical Infectious Diseases, 2012, 54, 853-861.	2.9	25
159	Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Review of Anti-Infective Therapy, 2020, 18, 1271-1279.	2.0	25
160	Role of serum free light chains in predicting HIVâ€associated nonâ€Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. American Journal of Hematology, 2012, 87, 749-753.	2.0	24
161	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	2.3	24
162	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1â€“Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 292-300.	0.9	24

#	Article	IF	Citations
163	The EuroSIDA study: 25 years of scientific achievements. HIV Medicine, 2020, 21, 71-83.	1.0	24
164	Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 574-581.	0.9	23
165	Life Expectancy in the Immune Recovery Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 175-181.	0.9	23
166	Declining Incidence of AIDS and Increasing Prevalence of AIDS Presenters Among AIDS Patients in Italy. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 663-669.	1.3	22
167	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. Aids, 2014, 28, 2269-2279.	1.0	22
168	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	0.9	22
169	Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. International Journal of Molecular Sciences, 2019, 20, 5925.	1.8	22
170	Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. EClinicalMedicine, 2021, 36, 100914.	3.2	22
171	Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients. Research in Psychotherapy: Psychopathology, Process and Outcome, 2020, 23, 491.	0.4	22
172	Outcome of a Second-Line Protease Inhibitorâ€“Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 115-122.	0.9	21
173	Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. Aids, 2010, 24, 2590-2593.	1.0	21
174	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virusâ€“infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657.	2.9	21
175	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	1.3	21
176	Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations. Antiviral Therapy, 2003, 8, 209-214.	0.6	21
177	Role ofIn VitroStimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients. Clinical and Developmental Immunology, 2012, 2012, 1-9.	3.3	20
178	Assessment of radiological vertebral fractures in <scp>HIV</scp>â€infected patients: clinical implications and predictive factors. HIV Medicine, 2015, 16, 563-571.	1.0	20
179	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.4	20
180	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. Antiviral Therapy, 2016, 21, 495-506.	0.6	20

#	Article	IF	Citations
181	Association Between Impaired VÎ±7.2+CD161++CD8+ (MAIT) and VÎ±7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients. Frontiers in Microbiology, 2019, 10, 1972.	1.5	20
182	Prevalence of HIV-1 Primary Drug Resistance in Seroconverters of the ICoNA Cohort Over the Period 1996???2001. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 761-764.	0.9	19
183	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	0.9	19
184	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health, 2018, 18, 870.	1.2	19
185	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. Aids, 2019, 33, 759-762.	1.0	19
186	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃ¯ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004â€“2014. HIV Medicine, 2019, 20, 99-109.	1.0	19
187	The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy. Frontiers in Public Health, 2020, 8, 575029.	1.3	19
188	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. Antiviral Therapy, 2006, 11, 609-618.	0.6	19
189	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ¯ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	1.0	18
190	CD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 642-644.	0.9	18
191	Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. Frontiers in Immunology, 2021, 12, 639291.	2.2	18
192	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	3.9	17
193	Predicting the magnitude of short-term CD4⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 165-175.	0.6	16
194	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. PLoS ONE, 2011, 6, e26009.	1.1	16
195	What Do We Know about Antiretroviral Treatment of HIV in Women?. Antiviral Therapy, 2013, 18, 27-34.	0.6	16
196	Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 347-352.	0.9	16
197	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. Open Forum Infectious Diseases, 2020, 7, ofaa456.	0.4	16
198	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 579-586.	0.9	16

#	Article	IF	Citations
199	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
200	Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems. Antiviral Therapy, 2004, 9, 743-752.	0.6	16
201	Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir. AIDS Research and Human Retroviruses, 2006, 22, 132-138.	0.5	15
202	Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral Therapy. Journal of Infectious Diseases, 2015, 211, 1511-1513.	1.9	15
203	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS ONE, 2017, 12, e0177402.	1.1	15
204	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	3.2	15
205	What do the changing patterns of comorbidity burden in people living with HIV mean for longâ€term management? Perspectives from European HIV cohorts. HIV Medicine, 2020, 21, 3-16.	1.0	15
206	Time spent with HIV-RNAâ€Šâ‰â€Š200â€Šcopies/ml in a cohort of people with HIV during the U=U era. Aids, 2021, 35, 1103-1112.	1.0	15
207	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 339-345.	0.9	14
208	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. Aids, 2018, 32, 1361-1367.	1.0	14
209	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 3295-3304.	1.3	14
210	Causeâ€specific mortality after diagnosis of cancer among HIVâ€positive patients: A collaborative analysis of cohort studies. International Journal of Cancer, 2020, 146, 3134-3146.	2.3	14
211	Risk for Nonâ€“AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	2.0	14
212	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. Health Policy, 2005, 74, 304-313.	1.4	13
213	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS ONE, 2017, 12, e0177352.	1.1	13
214	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	1.0	13
215	Successful directâ€acting antiviral therapy in HIV/HCV coâ€infected patients fails to restore circulating mucosalâ€associated invariant T cells. European Journal of Immunology, 2019, 49, 1127-1129.	1.6	13
216	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. New Microbiologica, 2016, 39, 93-109.	0.1	13

#	Article	IF	Citations
217	Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes. Antiviral Therapy, 2003, 8, 27-35.	0.6	13
218	Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. AIDS Research and Treatment, 2012, 2012, 1-10.	0.3	12
219	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	3.0	12
220	Unconventional T cells in chronic hepatitis B patients on longâ€term suppressive therapy with tenofovir followed by a Pegâ€<scp>IFN</scp> addâ€on strategy: A randomized study. Journal of Viral Hepatitis, 2018, 25, 381-390.	1.0	12
221	Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clinical Microbiology and Infection, 2018, 24, 422-427.	2.8	12
222	The importance of patientsâ€™ case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. International Journal of Infectious Diseases, 2020, 100, 67-74.	1.5	12
223	Dyslipidaemia after switch to tenofovir alafenamide (TAF)â€based cART regimens in a cohort of HIVâ€positive patients: what clinical relevance?. HIV Medicine, 2021, 22, 140-145.	1.0	12
224	The impact of DAAâ€mediated HCV eradication on CD4⁺ and CD8⁺ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort. Journal of Viral Hepatitis, 2021, 28, 779-786.	1.0	12
225	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). Journal of NeuroVirology, 2003, 9, 47-53.	1.0	12
226	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. Aids, 2013, 27, 1641-1655.	1.0	11
227	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	1.3	11
228	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Journal of Clinical Virology, 2020, 130, 104534.	1.6	11
229	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. Viruses, 2020, 12, 791.	1.5	11
230	Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?. International Journal of Infectious Diseases, 2020, 99, 75-76.	1.5	11
231	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	1.1	11
232	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiologica, 2018, 41, 247-255.	0.1	11
233	The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?. Antiviral Therapy, 2004, 9, 811-817.	0.6	11
234	Reduced HIV symptoms and improved health-related quality of life correlate with better access to care for HIV-1 infected women: the ELLA study. Journal of the International AIDS Society, 2014, 17, 19616.	1.2	10

#	Article	IF	Citations
235	Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapyâ€“Experienced Patients: A Multicenter Clinical Experience. HIV Clinical Trials, 2014, 15, 140-150.	2.0	10
236	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	1.0	10
237	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	1.3	10
238	Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infectious Diseases, 2019, 19, 881.	1.3	10
239	Declining Mortality Rate of Hospitalised Patients in the Second Wave of the COVID-19 Epidemics in Italy: Risk Factors and the Age-Specific Patterns. Life, 2021, 11, 979.	1.1	10
240	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, .	2.2	10
241	Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation. Aids, 2001, 15, 2201-2203.	1.0	9
242	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health, 2023, 117, 181-189.	1.0	9
243	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. Journal of Antimicrobial Chemotherapy, 2013, 68, 2205-2209.	1.3	8
244	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. Aids, 2016, 30, 1629-1637.	1.0	8
245	European <scp>AIDS</scp> Clinical Society Standard of Care meeting on <scp>HIV</scp> and related coinfections: The Rome Statements. HIV Medicine, 2016, 17, 445-452.	1.0	8
246	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clinical Infectious Diseases, 2016, 64, ciw846.	2.9	8
247	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1637-1642.	1.3	8
248	Out of focus: tailoring the cascade of care to the needs of women living with HIV. HIV Medicine, 2017, 18, 3-17.	1.0	8
249	Antiretroviral pill count and clinical outcomes in treatmentâ€naÃ¯ve patients with <scp>HIV</scp> infection. HIV Medicine, 2018, 19, 132-142.	1.0	8
250	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	1.3	8
251	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	1.9	8
252	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	1.3	8

#	Article	IF	Citations
253	Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?. Open Forum Infectious Diseases, 2020, 7, ofaa340.	0.4	8
254	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clinical Infectious Diseases, 2021, 73, 195-202.	2.9	8
255	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. Aids, 2021, 35, 2341-2346.	1.0	8
256	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
257	Italian multicentre study of didanosine compassionate use in advanced HIV infection. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 135-142.	1.3	7
258	Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study. Aids, 2005, 19, 1934-1936.	1.0	7
259	Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 149-150.	2.9	7
260	HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. Journal of Sexually Transmitted Diseases, 2013, 2013, 1-8.	1.0	7
261	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS ONE, 2015, 10, e0124252.	1.1	7
262	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS ONE, 2015, 10, e0140877.	1.1	7
263	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care and STDs, 2017, 31, 487-494.	1.1	7
264	Serious clinical events in HIV-positive persons with chronic kidney disease. Aids, 2019, 33, 2173-2188.	1.0	7
265	Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study. Antibiotics, 2021, 10, 1031.	1.5	7
266	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. Journal of Clinical Medicine, 2021, 10, 3752.	1.0	7
267	Predictors of low ovarian reserve in cART-treated women living with HIV. Medicine (United States), 2021, 100, e27157.	0.4	7
268	Early diagnosis of HIV infection in infants. Aids, 1989, 3, 391-396.	1.0	6
269	Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2003, 51, 171-174.	1.3	6
270	Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. Journal of Antimicrobial Chemotherapy, 2005, 55, 1003-1007.	1.3	6

#	Article	IF	Citations
271	Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin. Journal of Medical Microbiology, 2008, 57, 1431-1433.	0.7	6
272	Exposure to Abacavir and Biomarkers of Cardiovascular Disease in HIV-1â€"Infected Patients on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e98-e101.	0.9	6
273	Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19653.	1.2	6
274	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
275	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials, 2018, 19, 52-60.	2.0	6
276	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	1.9	6
277	Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment. PLoS ONE, 2014, 9, e110287.	1.1	6
278	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir Â± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	1.1	6
279	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiologica, 2015, 38, 443-90.	0.1	6
280	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	2.3	5
281	Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Research and Treatment, 2012, 2012, 1-7.	0.3	5
282	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load â‰¤50 copies/mL in the observational setting. Antiviral Therapy, 2013, 19, 319-324.	0.6	5
283	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. Journal of the International AIDS Society, 2014, 17, 19825.	1.2	5
284	Highlights on HIV eradication in 2013. Aids, 2014, 28, 1-7.	1.0	5
285	T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study. Antiviral Therapy, 2015, 21, 133-142.	0.6	5
286	Illness Representations of HIV Positive Patients Are Associated with Virologic Success. Frontiers in Psychology, 2016, 7, 1991.	1.1	5
287	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	1.3	5
288	Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. BMC Infectious Diseases, 2018, 18, 8.	1.3	5

#	Article	IF	Citations
289	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. PLoS ONE, 2018, 13, e0190302.	1.1	5
290	Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. Aids, 2019, 33, S271-S281.	1.0	5
291	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	1.2	5
292	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	1.1	5
293	Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice. BMC Infectious Diseases, 2021, 21, 1132.	1.3	5
294	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. Antiviral Therapy, 2001, 6, 195-198.	0.6	5
295	Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen. Biomedicine and Pharmacotherapy, 2001, 55, 16-22.	2.5	4
296	Cerebrovascular disease in highly active antiretroviral therapyâ€“treated individuals: Incidence and risk factors. Journal of NeuroVirology, 2005, 11, 34-37.	1.0	4
297	Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients. Journal of Visualized Experiments, 2011, , .	0.2	4
298	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. Journal of the International AIDS Society, 2014, 17, 19806.	1.2	4
299	Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Journal of the International AIDS Society, 2014, 17, 19769.	1.2	4
300	Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 258-267.	0.9	4
301	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 465-471.	0.9	4
302	Haemoptysis and fever in a young refugee from Somalia. International Journal of Infectious Diseases, 2018, 77, 57-60.	1.5	4
303	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	1.2	4
304	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1857-1865.	1.3	4
305	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. Antiviral Therapy, 2019, 24, 321-331.	0.6	4
306	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. Aids, 2021, 35, 2025-2033.	1.0	4

#	Article	IF	Citations
307	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infectious Diseases, 2021, 21, 557.	1.3	4
308	Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses, 2021, 13, 1402.	1.5	4
309	Resilience, Psychological Well-Being and Daily Functioning Following Hospitalization for Respiratory Distress Due to SARS-CoV-2 Infection. Healthcare (Switzerland), 2021, 9, 1161.	1.0	4
310	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naÃ¯ve HIV-infected patients starting antiretroviral therapy. International Journal of Antimicrobial Agents, 2021, 58, 106406.	1.1	4
311	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 132-137.	0.9	4
312	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. PLoS ONE, 2017, 12, e0189045.	1.1	4
313	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. Vaccines, 2022, 10, 550.	2.1	4
314	HCV reinfection after HCV therapy among HIV/HCVâ€coinfected individuals in Europe. HIV Medicine, 2022, 23, 684-692.	1.0	4
315	Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid. Annals of the New York Academy of Sciences, 1994, 724, 170-172.	1.8	3
316	Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports. Aids, 2008, 22, 1094-1097.	1.0	3
317	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. Journal of Global Antimicrobial Resistance, 2016, 7, 1-7.	0.9	3
318	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). Journal of NeuroVirology, 2018, 24, 679-694.	1.0	3
319	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008â€“2018 in Italy. Journal of Clinical Medicine, 2021, 10, 3391.	1.0	3
320	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.4	3
321	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiologica, 2018, 41, 112-117.	0.1	3
322	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. HIV Medicine, 2022, 23, 639-649.	1.0	3
323	Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients. Journal of Biological Regulators and Homeostatic Agents, 2020, 34, 1553 -1559.	0.7	3
324	Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patients With Poor Immunologic Response to HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 277-278.	0.9	2

#	Article	IF	Citations
325	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. Journal of the International AIDS Society, 2014, 17, 19509.	1.2	2
326	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. Medicine (United States), 2016, 95, e4434.	0.4	2
327	Brief Report: Drop in CD4+ Counts Below 200 Cells/Î¼L After Reaching (or Starting From) Values Higher than 350 Cells/Î¼L in HIV-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 417-422.	0.9	2
328	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 871-881.	1.3	2
329	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. Antiviral Therapy, 2018, 23, 633-637.	0.6	2
330	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naÃ¯ve, HIV-1-infected patients. HIV Clinical Trials, 2018, 19, 158-162.	2.0	2
331	Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. Clinical Drug Investigation, 2019, 39, 1239-1249.	1.1	2
332	Chest pain and a left parasternal soft tissue swelling in an immunocompetent refugee with disseminated tuberculosis. International Journal of Infectious Diseases, 2020, 90, 116-118.	1.5	2
333	Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study. BMC Infectious Diseases, 2020, 20, 812.	1.3	2
334	Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice. Health Economics Review, 2020, 10, 27.	0.8	2
335	Ability to Monitor National Responses to the HIV Epidemic â€œBeyond Viral Suppressionâ€: Findings From Six European Countries. Frontiers in Public Health, 2020, 8, 36.	1.3	2
336	Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect. Journal of Chemotherapy, 2021, 33, 238-244.	0.7	2
337	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infectious Diseases, 2021, 8, ofaa566.	0.4	2
338	Persistence of High Peripheral Activated CD8+ T-cells and Not a Low CD4:CD8 Ratio Predict cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects. Open Forum Infectious Diseases, 2022, 9, ofac046.	0.4	2
339	Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy â€“ The CHILI study. Travel Medicine and Infectious Disease, 2022, 48, 102324.	1.5	2
340	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV Medicine, 2022, 23, 585-598.	1.0	2
341	HIV priorities by Italian AIDS advocacy groups: information on prevention (still) comes first. An on-line survey. Epidemiologia E Prevenzione, 2019, 43, 270-274.	1.1	2
342	Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy. Current HIV Research, 2008, 6, 560-562.	0.2	1

#	Article	IF	Citations
343	Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender. Journal of the International AIDS Society, 2014, 17, 19717.	1.2	1
344	Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. PLoS ONE, 2019, 14, e0212075.	1.1	1
345	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load â‰¤50 copies/mL: does estimated glomerular filtration rate matter?. International Journal of Antimicrobial Agents, 2020, 56, 106154.	1.1	1
346	Safety and efficacy of daclatasvir at doses other than 60â€¯mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Digestive and Liver Disease, 2020, 52, 447-451.	0.4	1
347	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. Scientific Reports, 2021, 11, 9632.	1.6	1
348	SARS-CoV-2 and the nervous system: review on pathogenesis of nervous system SARS-CoV-2 damage. , 0, , .		1
349	Partnership of HIV-Infected Women and Health Status. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 502-503.	0.9	0
350	Longâ€term probability of detecting drugâ€resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection. Journal of the International AIDS Society, 2010, 13, O4.	1.2	0
351	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Services Research, 2012, 12, 38.	0.9	0
352	Viro-immunological characterization of naÃ¯ve patients with high cerebrospinal fluid (CSF) HIV RNA. Journal of the International AIDS Society, 2014, 17, 19710.	1.2	0
353	Reply to Manfredi. Journal of Infectious Diseases, 2015, 211, 1357-9.	1.9	0
354	A 20-year-old girl with an unusual febrile illness. Internal and Emergency Medicine, 2021, , 1.	1.0	0
355	Renal microsporidiosis due to Encephalitozoon cuniculi in an HIV/AIDS patient with persistent fever and kidney injury. Clinical Microbiology and Infection, 2021, 27, 1439-1440.	2.8	0
356	A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy. Frontiers in Public Health, 2021, 9, 639347.	1.3	0
357	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
358	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy. Journal of Clinical Medicine, 2022, 11, 471.	1.0	0
359	Beyond Italian guidelines in the management of HIV-positive patient. Infezioni in Medicina, 2020, 28, 587-596.	0.7	0
360	<scp>HIVâ€NAAT</scp> use for early detection of <scp>HIV</scp> infection among highâ€risk men who have sex with men in Italy. HIV Medicine, 2023, 24, 239-241.	1.0	0